Containment Engineer In-Vivo Vaccination 
The Pharma Data
DECEMBER 10, 2020
–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. CULVER CITY, Calif.–( Graphic: Business Wire).
XTalks
AUGUST 17, 2020
With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. protein-based biologics) and vaccine treatments. Treatment vaccines : these boost the immune system responses to target cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 11, 2021
Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.
Drug Discovery World
NOVEMBER 15, 2022
The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. If there’s a mismatch between two strands, the DNA will melt away at a lower temperature.
Drug Discovery World
NOVEMBER 30, 2023
DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. GSK has developed high-throughput mammalian and E.
Drug Discovery World
FEBRUARY 1, 2024
From this enriched selection, promising candidates are identified only after each antibody is characterised both in vitro and in vivo. For over a year, Evusheld provided prophylactic protection for immunocompromised people, a group that was often unable to benefit from vaccines.
The Pharma Data
OCTOBER 26, 2020
Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Key findings of the trial: .
Expert insights. Personalized for you.
52 
Let's personalize your content